Table 1

Clinicopathological characteristics of the patients

VariablesNumber of patients (%) expressing ERβ
<10%10–40%>40%
ER, oestrogen receptor; PR, progesterone receptor.
Menopausal status
    Before menopause (n = 39)12 (30.7%)17 (43.5%)10 (25.6%)
    After menopause (n = 142)40 (28.1%)54 (38%)48 (33.8%)
Tumour maximum diameter
    <2 cm (n = 49)12 (24.4%)20 (40.8%)17 (34.7%)
    >2 cm (n = 132)40 (30.3%)51 (38.6%)41 (31%)
Histological type
    Invasive ductal not otherwise specified (n = 149)41 (27.5%)63 (42.3%)45 (30.2%)
    Invasive lobular (n = 32)11 (34.3%)8 (25%)13 (40.6%)
Histological grade (in ductal invasive carcinomas only)
    I (n = 13)4 (30.7%)7 (53.8%)2 (15.4%)
    II (n = 91)24 (26.4%)37 (40.6%)30 (33%)
    III (n = 43)12 (27.9%)19 (44.2%)12 (27.9%)
Nuclear grade
    I (n = 71)17 (24%)29 (40.8%)25 (35.2%)
    II (n = 60)17 (28.3%)20 (33.3%)23 (38.3%)
    III (n = 47)16 (34%)21 (44.7%)10 (21.3%)
Lymph node status
    Tumour free (n = 69)16 (23.2%)27 (39.1%)26 (37.7%)
    Tumour infiltrated (n = 112)36 (32.1%)44 (39.3%)32 (28.6%)
Stage
    I (n = 29)6 (20.7%)12 (41.4%)11 (38%)
    II (n = 126)37 (29.4%)46 (36.5%)43 (34.1%)
    III (n = 26)9 (34.6%)13 (50%)4 (15.4%)
ERα immunostatus
    Negative (n = 61)27 (44.3%)24 (39.3%)10 (16.4%)
    Positive (n = 117)23 (19.6%)46 (39.3%)48 (41%)
PR immunostatus
    Negative (n = 91)28 (30.8%)35 (38.5%)28 (30.8%)
    Positive (n = 87)22 (25.3%)35 (40.2%)30 (34.5%)